EssityESSITY B
ESSITY B logo
Fair Value
SEK 219.4
Share price15 Jul
SEK 282.828.9% overvalued intrinsic discount
Loading
1Y15.15%
7D1.76%

Regulatory Pressures And Cost Hikes Will Squeeze Hygiene Margins

Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
20 Jul 25
Updated
15 Jul 26
Views
42
Not Invested

Last Update 15 Jul 26

Fair value Increased 2.04%

ESSITY B: Ongoing Pricing And Margin Concerns Will Continue To Pressure Sentiment

The analyst price target for Essity has edged higher from SEK 215 to about SEK 219, with analysts pointing to updated assumptions on fair value, revenue growth and profit margins, even as they weigh recent Street research such as the JPMorgan downgrade.

What’s in the News for Essity

  • Essity plans to commence share repurchases on May 12, 2026, under an authorization from the March 26, 2026 Annual General Meeting, with scope to buy back shares so that the company does not hold more than 10% of its issued share capital. [Source: Company announcement]
  • The share repurchases will take place on Nasdaq Stockholm, at prices within the prevailing market price interval between the highest purchase price and lowest selling price on the marketplace. [Source: Company announcement]
  • The company states that the purpose of the buyback mandate is to adapt Essity’s capital structure, with repurchased shares intended for use as payment or financing for potential acquisitions of companies or businesses, and with an aim of contributing to shareholder value. [Source: Company announcement]
  • On April 22, 2026, Essity announced a specific share repurchase program of up to SEK 3,000 million of its B shares, financed by cash flow from current operations after the ordinary dividend. The repurchased shares are expected to be cancelled, and the company has expressed an ambition to continue buybacks over time as a recurring capital allocation tool. [Source: Company announcement]
  • Essity’s Board of Directors has initiated a strategic review of the Consumer Tissue business area, evaluating different alternatives for ownership that may include a separation. The review is described as part of efforts to optimize the product portfolio and focus on long term value creation. [Source: Company announcement / management comment]

Valuation Changes for Essity

  • Fair Value: SEK 215.0 in the prior model compared with SEK 219.4 in the updated assessment, described as a modest upward adjustment.
  • Discount Rate: Held unchanged at 5.34%, indicating no revision to the assumed cost of capital in the Essity valuation work.
  • Revenue Growth: Assumption adjusted from 1.91% to 2.19%, reflecting a slightly higher projected SEK revenue growth rate in the model.
  • Net Profit Margin: Margin assumption revised from 9.17% to 9.34%, implying a small uplift in expected SEK earnings as a share of revenue.
  • Future P/E: Forward P/E multiple moved from 12.39x to 12.31x, a marginal reduction in the valuation multiple applied to Essity’s earnings.
1 viewusers have viewed this narrative update

Key Takeaways

  • Rising regulations and sustainability trends are set to hinder Essity's traditional product demand and increase compliance and operational costs.
  • Intensifying competition and consumer shifts toward reusables threaten Essity's pricing power and revenue growth across key markets.
  • Strong pricing power, innovation, and cost-saving initiatives underpin Essity's revenue growth, margin resilience, and competitive positioning amid market volatility and evolving consumer demand.

Catalysts

About Essity
    Develops, produces, and sells hygiene and health products and services in Europe, North and Latin America, Asia, and internationally.
What are the underlying business or industry changes driving this perspective?
  • Growing environmental regulations and the accelerating pushback against single-use plastics are set to constrain demand for disposable hygiene products, increasing compliance costs, and potentially reducing core revenue streams for Essity over the long term.
  • The demographic trend of aging populations in developed markets could shift demand away from traditional incontinence and tissue products toward alternatives such as reusables or advanced medical solutions, which threatens sustained sales momentum in Essity's key segments.
  • Prolonged difficulties in fully passing increased raw material, energy, and distribution costs onto consumers, combined with ongoing cost inflation, are likely to continue compressing Essity's gross and net margins, even as competition intensifies.
  • Expansion of private label and low-cost competitors, particularly in Europe and North America, is expected to erode volume growth and force further price competition, undermining Essity's branded revenue and profitability over time.
  • Sector-wide substitution toward reusable and more sustainable alternatives in baby, feminine, and tissue products is likely to erode category volumes and pricing power for Essity, resulting in long-term revenue and earnings headwinds.
Essity Earnings and Revenue Growth

Essity Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • This narrative explores a more pessimistic perspective on Essity compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
  • The bearish analysts are assuming Essity's revenue will grow by 2.2% annually over the next 3 years.
  • The bearish analysts assume that profit margins will increase from 9.1% today to 9.3% in 3 years time.
  • The bearish analysts expect earnings to reach SEK 13.6 billion (and earnings per share of SEK 20.34) by about July 2029, up from SEK 12.5 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as SEK16.0 billion.
  • In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 12.3x on those 2029 earnings, down from 15.2x today. This future PE is lower than the current PE for the GB Household Products industry at 22.9x.
  • The bearish analysts expect the number of shares outstanding to decline by 1.31% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 5.34%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Persistent pricing power and successful price management across multiple segments-even in the face of raw material and tariff cost increases-have allowed Essity to fully offset margin headwinds, supporting resilient gross profit and protecting net earnings.
  • Sustained growth and market share gains in strategic categories such as Feminine Care, Incontinence Care Retail, and Wound Care across diverse geographies are driving higher-value sales, underpinning revenue strength and margin expansion over time.
  • Ongoing innovation, brand investment, and tiered product strategies enable Essity to tap into both premium and value segments, preserving competitiveness and protecting volume and revenue growth even as consumer price-sensitivity fluctuates.
  • Targeted, ongoing cost-saving initiatives in both COGS and SG&A, combined with efficiency improvements in supply chain and digitalization, position Essity to mitigate cost inflation and enhance profit margins in future periods.
  • Recognition for sustainability leadership and impactful brand campaigns enhances long-term brand equity, supports premium pricing, and could drive customer loyalty, all of which may contribute positively to both revenue and profit growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The assumed bearish price target for Essity is SEK219.4, which represents up to two standard deviations below the consensus price target of SEK271.47. This valuation is based on what can be assumed as the expectations of Essity's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of SEK310.0, and the most bearish reporting a price target of just SEK215.0.
  • In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be SEK145.9 billion, earnings will come to SEK13.6 billion, and it would be trading on a PE ratio of 12.3x, assuming you use a discount rate of 5.3%.
  • Given the current share price of SEK278.6, the analyst price target of SEK219.4 is 27.0% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Essity?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

SEK 219.4
vs SEK 282.828.9% overvalued intrinsic discount
PastFuture0146b2015201820212024202620272029Revenue SEK 145.9bEarnings SEK 13.6b
2.2%
Revenue growth
9.3%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Essity

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Flawless balance sheet and undervalued.

Market capSEK 191.7b
PB2.1x
Estimated Growth3.0%
Dividend Yield3.1%
Full analysis

CEO & management

Ulrika Kolsrud
CEO
2.9yrs
CEO Tenure

Develops, produces, and sells hygiene and health products and services in Europe, North and Latin America, Asia, and internationally.